NMR studies of V3 peptide complexes with antibodies suggest a mechanism for HIV-1 co-receptor selectivity

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 5, 2005, Pages 601-612

  Sharon, Michal ^a   Rosen, Osnat ^a   Anglister, Jacob ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

HIV 1 co receptor; HIV 1 GP120; NMR of antibodies; V3

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; PEPTIDE; UNCLASSIFIED DRUG; V3 PEPTIDE;

ANTIGEN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR BINDING; RECEPTOR INTRINSIC ACTIVITY; REVIEW; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; RECEPTORS, CHEMOKINE;

EID: 24044512965     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism and disease. Annu Rev Immunol (1999) 17:657-700.
2. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K et al: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 313(6000):277-284.
3. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 70(2):1100-1108.
4. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C et al: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 384(6605):179-183.
5. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 2(11):1244-1247.
6. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol (1992) 66(11):6777-6780. One of the first studies demonstrating that residue 329 within the V3 of gp120 has a major influence on HIV-1 tropism. The discovery in 1996 that CCR5 and CXCR4 serve as co-receptors for HIV-1 infection enabled the correlation of the phenotype switch with co-receptor selectivity.
7. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393(6686):648-659.
8. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold Des (2000) 8(12):1329-1339.
9. VanCott TC, Bethke FR, Polonis VR, Gomy MK, Zolla-Pazner S, Redfield RR, Birx DL: Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 153(1):449-459.
10. Skinner MA, Ting R, Langlois AJ, Weinhold KJ, Lyerly HK, Javaherian K, Matthews TJ: Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Res Hum Retroviruses (1988) 4(3):187-197.
11. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H, Javaherian K, Takatsuki K, Putney S: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 62(6):2107-2114.
12. Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 72(9):6988-6996.
13. Conley AJ, Gomy MK, Kessler JA 2nd, Boots LJ, Ossorio-Castro M, Koenig S, Lineberger DW, Emini EA, Williams C, Zolla-Pazner S: Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 68(11):6994-7000.
14. Tugarinov V, Zvi A, Levy R, Hayek Y, Matsushita S, Anglister J: NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Structure Fold Des (2000) 8(4):385-395. Presents the first NMR structure of the Fv complex and the first structure (resolved either by X-ray or NMR) of an antibody fragment in complex with a β-hairpin formed by the V3. The structure reveals a surface important for co-receptor binding.
15. MN peptides bound to 447-52D. This paper also suggests that the breadth of neutralization by antibodies has a molecular basis.
16. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J: Alternative conformations of HIV-1 V3 loops mimic β hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (2003) 11(2):225-236. Demonstrates that the V3 adopts alternative β-hairpin conformations. Analogy is found with the CCR5 and CXCR4 chemokines that show similar alternative conformations of the β2,β3-hairpin despite overall structural similarity between all chemokines.
17. Balaram P, Bothner-By AA, Dadok J: Negative nuclear Overhauser effects as probes of macromolecular structure. J Am Chem Soc (1972) 94(11):4015-4017.
18. Ikura M, Bax A: Isotope filtered 2D NMR of a protein-peptide complex: Study of a skeletal muscle myosin light chain kinase fragment bound to calmodulin. J Am Chem Soc (1992) 114(7):2433-2440.
19. Fesik SW, Luly JR, Erickson JW, Abad-Zapatero C: Isotope-edited proton NMR study on the structure of a pepsin/inhibitor complex. Biochemistry (1988) 27(22):8297-8301.
20. Sharon M, Gorlach M, Levy R, Hayek Y, Anglister J: Expression, purification and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies. Protein Expr Purif (2002) 24(3):374-383.
21. Kessler N, Zvi A, Ji M, Sharon M, Rosen O, Levy R, Gorny M, Zolla-Pazner S, Anglister J: Expression, purification and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies. Protein Expr Purif (2003) 29(2):291-303.
22. IIIB V3 peptide. Nat Struct Biol (1999) 6(4):331-335. Provides the first well-defined β-hairpin structure of the V3 in complex with an antibody fragment, and demonstrates that the V3 adopts different types of turns in different antibody complexes.
23. Zvi A, Feigelson DJ, Hayek Y, Anglister J: Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy. Biochemistry (1997) 36(28):8619-8627.
24. Ghiara JB, Stura EA, Stanfield RL, Profy AT, Wilson IA: Crystal structure of the principal neutralization site of HIV-1. Science (1994) 264(5155):82-85.
25. Stanfield R, Cabezas E, Satterthwait A, Stura E, Profy A, Wilson I: Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing Fabs. Structure (1999) 7(2):131-142. Provides the first structural indication that the V3 loop has alternative conformations.
26. Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, Wilson IA: Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Virology (2003) 315(1):159-173.
27. Rini JM, Stanfield RL, Stura EA, Salinas PA, Profy AT, Wilson IA: Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci USA (1993) 90(13):6325-6329.
28. MN peptide. The V3 peptide forms an intermolecular β-sheet with CDR3 of 447-52D heavy chain. Although shorter, this structure adopts the same general fold as observed in the NMR structure.
29. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P et al: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science (1990) 249(4971):932-935. Predicts that the segments flanking the GPGR sequence form β-strands in most HIV-1 isolates.
30. Hansen JE, Lund O, Nielsen JO, Brunak S, Hansen JE: Prediction of the secondary structure of HIV-1 gp120. Proteins (1996) 25(1):1-11.
31. Gozansky EK, Louis JM, Caffrey M, Clore GM: Mapping the binding of the N-terminal extracellular tail of the CXCR4 receptor to stromal cell-derived factor1α J Mol Biol (2005) 345(4):651-658. Provides direct experimental evidence for the participation of the β2,β3-hairpin of SDF-1 in CXCR4 binding.
32. Graham GJ, Wilkinson PC, Nibbs RJ, Lowe S, Kolset SO, Parker A, Freshney MG, Tsang ML, Pragnell IB: Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP-1α by mutagenesis of the proteoglycan binding site. EMBO J (1996) 15(23):6506-6515.
33. Laurence JS, Blanpain C, De Leener A, Parmentier M, LiWang PJ: Importance of basic residues and quaternary structure in the function of MIP-1β: OCR5 binding and cell surface sugar interactions. Biochemistry (2001) 40(16):4990-4999.
34. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ: Selective Interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol(2000) 74(4):1948-1960.
35. Lusso P: Picking the lock with a hairpin. Did HIV-1 learn the art from chemokines? Structure (2003) 11(2):129-130. Evaluates the significance of the proposed NMR model for co-receptor specificity and points to the shortcomings of the model, which should be examined by conducting further experiments.
36. Hartley O, Klasse PJ, Sattentau QJ, Moore JP: V3: HIVs switch-hitter. AIDS Res Hum Retroviruses (2005) 21(2):171-189. Provides a comprehensive review on the V3 region.
37. Wang WK, Dudek T, Essex M, Lee TH: Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: Therapeutic and prophylactic implications. Proc Natl Acad Sci USA (1999) 96(8):4558-4562.
38. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ et al: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 78(23):13232-13252. Provides an exhaustive examination of the neutralization of HIV-1 by the few antibodies that broadly neutralize the virus.
39. Zolla-Pazner S: Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol (2004) 4(3):199-210.
40. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT: HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 5(3):233-236.
41. Kwong PD: The 447-52D antibody: Hitting HIV-1 where its armor is thickest. Structure (2004) 12(2):173-174. Describes the difficulties in broad HIV-1 neutralization by antibodies directed against the V3 and comments on how 447-52D antibody alleviated these difficulties.
42. Chandrasekhar K, Profy AT, Dyson HJ: Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120. Biochemistry (1991) 30(38):9187-9194.
43. IIIB: A two-dimensional NMR study. Biochemistry (1992) 31(30):6972-6979.
44. Cabezas E, Wang M, Parren PW, Stanfield RL, Satterthwait AC: A structure-based approach to a synthetic vaccine for HIV-1. Biochemistry (2000) 39(47):14377-14391.
45. Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T: T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol (1998) 72(12):9763-9770.
46. Rabehi L, Seddiki N, Benjouad A, Gluckman JC, Gattegno L: Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages. AIDS Res Hum Retroviruses (1998) 14(18):1605-1615.
47. Lodi PJ, Garrett DS, Kuszewski J, Tsang ML, Weatherbee JA, Leonard WJ, Gronenborn AM, Clore GM: High-resolution solution structure of the β chemokine hMIP-1 β by multidimensional NMR. Science (1994) 263(5154):1762-1767.
48. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD, Clark-Lewis I: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J (1997) 16(23):6996-7007.